$KNOP

KNOT Offshore Partners LP (KNOP): Financial results for H1 2026

KNOT Offshore Partners LP (KNOP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 KNOT OFFSHORE PARTNERS LP EARNINGS RELEASE—INTERIM RESULTS FOR THE PERIOD ENDED JUNE 30, 2026 KNOT Offshore Partners LP (NYSE:KNOP): Financial Highlights For the three months ended June 30, 2026 (“Q2 2026”), KNOT Offshore Partners LP (“KNOT Offshore Partners,” “we” o

Original reporting
Published Sep 3, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$KNOP
Bullish
high confidence
Mentioned
$KNOP
Relevance
7/10
alphai data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$KNOPBullishMed
01

Why it matters

The earnings release provides the first public disclosure of Q2 2026 performance and new charter extensions, offering a fresh data point for valuation.

02

Market read

Earnings beat and new long‑term charters could support KNOP's share price and influence sector peers.

03

What to watch

Potential exposure to volatile oil prices and regulatory changes in offshore emissions standards.

Relevance 7/10Novelty 8/10Timing: post‑release today

Background

KNOP is a publicly traded partnership focused on owning and operating shuttle tankers for oil transport.

Company-level read

Ticker impact

$KNOPBullishHigh confidence
Context

Q2 2026 earnings release reporting $96.8M revenue, $15.6M operating income and $3.4M net income.

Expected impact

Potential short‑term upside as investors digest solid results and new long‑term charter wins.

Evidence & confidence

First‑hand SEC 6‑K provides fresh, material financials and contract updates for a mid‑cap offshore shuttle tanker partnership.

Market effects

Reinforces strength in offshore shuttle tanker sector and may lift peer valuations.

Positive for North Sea and Brazil offshore charter markets where KNOP operates.

Limited to energy logistics niche; modest broader market effect.

Counterpoint

If charter extensions are delayed or vessel downtime recurs, earnings quality could deteriorate.

Key entities

  • KNOT Offshore Partners LP

    NYSE‑listed offshore shuttle tanker partnership.

  • Shell

    Extended charter for Live Knutsen vessel.

  • Equinor

    Extended charter for Synnøve Knutsen vessel.

Related articles

$KNOPHighAI 8/10

KNOT Offshore Partners LP Earnings Release-Interim Results for the Period Ended June 30, 2026

KNOT Offshore Partners LP (KNOP) reported Q2 2026 earnings with $96.8M revenue, $3.4M net income, and $57.6M Adjusted EBITDA. The company declared a $0.075 quarterly distribution and extended charters for several vessels. KNOP also refinanced $225M in debt and acquired the Hedda Knutsen shuttle tanker for $24.4M, subject to adjustments. The fleet operated at 96.8% utilization, and the company has secured 97% charter coverage for H2 2026 and 87% for H2 2027.

$HYMed

Hyster-Yale’s (HY) Bookings Boom Meets A Widening Loss

Hyster-Yale (HY) reported Q2 results with bookings up 106% YoY to $680M, but a net loss of $31.6M. Revenue rose 2% QoQ to $812.9M, and operating cash flow turned positive at $17M. Management expects full-year bookings to exceed 2025, but warns of slow margin recovery due to competitive pricing and tariffs.

$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.